SCHEMBL9917879

SCHEMBL9917879

NCC1(c2cc(F)cc(-c3ccnc4[nH]ncc34)c2)CCC1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 12/20 0.74
PRKCA P17252 2/20 0.48
PRKCD Q05655 2/20 0.48
KCNH2 Q12809 2/20 0.48
TLR9 Q9NR96 1/20 0.43
TLR8 Q9NR97 1/20 0.43
BRD4 O60885 1/20 0.43
NUDT1 P36639 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TLR7 Q9NYK1 1/20 0.41
CSNK1D P48730 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
TNIK Q9UKE5 1/20 0.39
USP30 Q70CQ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9917881 0.88 PRKCQ (0.75) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917834 0.87 PRKCQ (0.74) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917829 0.87 PRKCQ (0.70) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917880 0.85 PRKCQ (0.74) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917740 0.85 PRKCQ (1.00) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL13624661 0.85 PRKCQ (0.70) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917741 0.83 PRKCQ (1.00) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917868 0.82 PRKCQ (1.00) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917836 0.82 PRKCQ (0.68) PRKCQPRKCAPRKCDKCNH2TLR9
SCHEMBL9917844 0.80 PRKCQ (0.91) PRKCQPRKCAPRKCDKCNH2TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367697-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-05 US disclosed
US-8367697-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-05 US disclosed
US-20120149680-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-14 US disclosed
US-20120149680-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-14 US disclosed
US-8173635-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-08 US disclosed
US-8173635-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-08 US disclosed
US-20090291937-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-11-26 US disclosed
US-20090291937-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291937-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 PRKCQ 38/4885PRKCA 25/4885PRKCD 120/4885
US-20120149680-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 PRKCQ 38/4885PRKCA 25/4885PRKCD 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.